SPEAKERS:
- Mike Petroutsas, President, Head of US, Astellas
- Vicky Brown, SVP, US Franchise Head of Oncology and Emerging Areas, Boehringer Ingelheim
- Justin Holko, SVP, Head, Global Oncology/Hematology Commercial Business Unit, Regeneron Pharmaceuticals, Inc.
- Osama Hashmi, Dermatologist, CEO & Co-founder, Impiricus
- Jonathan Elliott, Content Director, Reuters Events
KEY TAKEAWAYS:
• Launch velocity comes from stripping organizational complexity, not accelerating parallel workstreams
• Quarterly planning cycles outperform annual ones by forcing explicit trade-offs every ninety days
• Post-launch complacency announces itself through language before it shows up in share metrics
• Omnichannel investment has created physician noise problems that now require active remediation
• AI extends field force capability at scale, but it cannot replace high-trust clinical relationships
Boehringer Ingelheim used a Commissioner's National Priority Voucher to reach approval in 44 days on its most recent oncology launch. The speed was extraordinary. What made it possible, Vicky Brown argued at Reuters Events: Pharma USA 2026, was not a more aggressive project plan, but a narrower one. "There's nothing about speed that comes more from that," Brown said, "but it makes you really focus on what's most important." Forty-four days compresses everything to essentials. The question the panel spent the next forty minutes examining is whether organizations can manufacture that same compression without a regulatory deadline forcing their hand.
The answer, across four commercial leaders from Astellas, Boehringer Ingelheim, Regeneron, and Impiricus, converged on a single structural argument: the pharma industry has confused launch speed with launch volume. The fastest organizations are not doing more. They are doing fewer things with higher decisional authority at lower levels of the org chart.
Speed Lives in the Org Chart
"Speed is fundamentally about decisions, not tactics," Jonathan Elliott observed, framing what became the session's most productive argument. Every panelist had a version of this claim, but Mike Petroutsas at Astellas had operationalized it most explicitly.
Astellas dismantled its conventional functional structure; marketing, sales, market access as separate lanes, and rebuilt around what it calls value teams. Each team is co-led by commercial and medical, sized small, and empowered to make decisions without escalating to functional heads. "It's all of decision-making, pushing it down in the organization," Petroutsas explained. "And I think that's where we derive our speed and that's what's driven the success of our launches." When the people closest to the market own the decision, the latency between insight and action collapses.
The planning cadence reinforces the structure. Astellas abandoned annual planning in favor of quarterly cycles. "At the start of every quarter, we align on each of the strategic assets, on what are the two or three things we need to get right," Petroutsas described. "The value teams are empowered in the next three months to deliver on those and they have a finite amount of time to do it. Not 12 months, three months." The constraint is the point. Twelve-month timelines absorb ambiguity; ninety-day cycles force explicit prioritization and create a regular cadence for stopping things that are not working. Budget can be reallocated across assets at each quarterly reset, which means underperforming investments get cut in weeks rather than surviving until the next annual planning season.
Regeneron's structural logic runs parallel but starts from a different origin. Justin Holko described building the global oncology commercial organization from scratch, without inherited hierarchy. "We've really built our global organization from the ground up and we're not wedded to hierarchy and structures and legacy footprints that others may be," he said. "It's been intentional to draw it up in a way that really maximizes simplicity." Where Astellas re-engineered an existing structure, Regeneron was able to build one fit-for purpose. The result in both cases is an organization where coordination costs are low enough that speed becomes the default rather than the exception.
What neither structure tolerates is the common compensatory move: when facing a competitive disadvantage at launch, flooding investment across every available channel. "Sometimes when we think about engagement, we think about quantity, not quality," Petroutsas acknowledged. "And often when we're not first to market, but we are well funded, we just throw everything at it, which I think has to stop." The org chart changes are only durable if paired with the discipline to concentrate resources rather than disperse them.
Complacency Has a Vocabulary
If organizational agility drives launch speed, what destroys it? Brown's answer was diagnostic and specific enough to be immediately actionable.
The signals are linguistic before they are metric. Brown identified three shifts she watches for in post-launch teams. First, the conversation moves from "what do we still need to do" to "how do we protect share." Second, evidence generation stops, the assumption forms that the data story is complete. Third, decision-making reverts to consensus, a reliable proxy for declining urgency. "It's subtle shifts in language where teams stop talking about ‘what is needed, what else do we need to do to fill the gaps, how do we further educate’ to ‘ how do we hang on to share’?" Brown described. The transition from offense to defense is rarely announced. It accumulates in meeting rooms, in how questions get framed, in which topics stop getting raised.
Her competitive read of what follows is direct: "The market isn't owned by who got there first. It's those who are looking for the gaps to improve and they're fulfilling them." In oncology especially, where the treatment landscape shifts faster than most annual planning cycles can track, static execution is a slow concession.
Holko's practice for fighting complacency is to challenge his teams to maintain launch energy in the years well beyond approval. "I challenge my teams to launch every year. We haven't had a lung cancer launch in four years. But when we go over our annual strategy, my first question to them is: how are you going to make this year feel like a launch again?" The ritual has a real purpose. Launch conditions produce a particular quality of attention, urgency, external orientation and a willingness to question assumptions that post-launch stability tends to erode. Making it a standing expectation rather than an event-driven response keeps that diagnostic muscle active.
Holko's broader framing of what a launch actually is reinforces the same logic. He described his first major launch: showing up in a suit and tie on the anticipated FDA approval, treating the regulatory event as the finish line. "I remember my first launch very vividly," he said. "We thought the FDA was going to approve us on a given Friday in March... and as time goes on, you figure out, well, there's a hell of a lot of work to do beyond that approval." Approval is closer to a starting pistol. Brown's own oncology program moved from second-line to frontline approval in under six months. That cadence requires treating every post-approval period as a pre-launch period for what comes next.
Discover more on this topic at Pharma Customer Engagement USA 2026 (October 27-28, Philadelphia) - where commercial, marketing, medical, data and AI pioneers converge. Explore the agenda here.
The Physician Isn't Receiving a Signal
Elliott's question to Osama Hashmi cut directly to where organizational agility either delivers value or disappears into noise: "Does pharma even ask you what appropriate speed is?" Hashmi's answer, offered from the unusual position of a practicing dermatologist who also runs a commercial technology company, reframed the omnichannel conversation entirely.
"We've had a lot of success on the pharma side in terms of omnichannel, but from a physician experience side, unfortunately, a lot of that has resulted in a lot of noise for the physician." The industry optimized for reach metrics, impressions, contact frequency, channel coverage, without accounting for the cumulative experience on the receiving end. A physician seeing 40 to 60 patients a day, managing inbox volume from multiple companies across multiple products, is not experiencing a coordinated engagement strategy. They are experiencing undifferentiated interference.
Hashmi's critique of the underlying assumption is pointed: "The clinician is viewed as kind of this outside animal... But in reality, like for me as a physician, younger physicians, older physicians, we're on TikTok, we're on Instagram, we have consumer experiences." The physician-as-sacred-academician framing has produced engagement models that feel nothing like how those same people interact with every other information source in their lives. Consumer experience design principles, relevance, timing, brevity, personalization, have not been systematically applied to HCP engagement, despite the fact that the target audience has the same cognitive architecture as any other consumer.
Brown's co-creation philosophy addresses the same gap from a different angle. Her mantra, "we don't approve it, we don't prescribe it, we don't pay for it, and I hope we never take it", is an institutional discipline against assuming the company understands what its external stakeholders need. No patient material leaves Boehringer without patient review. The approach is not customer-centricity as positioning. It is customer-centricity as quality control on the engagement itself.
The AI question arrived in this context, and Hashmi was precise about where the technology does and does not belong. "Will AI or technology ever be able to replace a really good rep experience, a really good MSL experience? The answer is no... The question is really thinking about how can AI extend their capabilities and allow them to operate at the top of their license." The rep who spends most of their time driving, cold-calling, and leaving materials at reception desks is not operating at the top of their license. AI absorbs that surface-level activity. What remains, the relationship, the clinical nuance, the trust that accumulates over time in a specific therapeutic area, is what the technology cannot replicate.
What Velocity Actually Requires
The convergence across all four panelists is not quite what the session title advertises. "Speed" is the right word for the outcome but the wrong mental model for the mechanism. Holko's formulation is the cleanest: "I'd rather be quick, but not in a hurry." He continued that hurry looks like activity multiplication, more channels, more contacts, more planning documents, more review cycles. Quickness looks like the opposite: fewer decisions made by senior people, replaced by more decisions made faster by empowered teams closer to the market. It looks like quarterly plans that force trade-offs rather than annual plans that defer them. It looks like biomarker infrastructure built before approval, not after.
Brown's point on this is unambiguous: in a precision medicine launch, the diagnostic pathway is as much a launch prerequisite as the label itself. Patients with HER2-mutated non-small cell lung cancer who are never tested never receive the therapy, regardless of how fast it was approved. The company that owns the first targeted indication owns the obligation to build the testing infrastructure, because no one else will.
Petroutsas extended this logic upstream. Insights around policy shifts, health system consolidation, and pricing environments need to feed into phase three trial design. "Before phase three trials are developed, the right insights are going in," he said. "Because five, six years from now, we're going to talk about pricing, and if we're not clear on what that environment looks like, speed won't really matter." A product that reaches market without the right evidence architecture for its commercial context will stall regardless of how fast it got there.
The organizations that consistently compress time-to-patient are not running faster. They are eliminating the organizational friction that makes speed feel like it requires more resources rather than fewer. That friction lives in governance structures that centralize decisions, planning cadences that defer prioritization, engagement models that optimize for activity rather than signal, and post-launch cultures that mistake stability for momentum. Companies that address it will find that the 44-day approval is less an outlier than a proof of concept, one that applies long after the regulatory clock stops running.
To get you highlights of Pharma USA 2026 faster, we are using generative AI technology to summarise the transcripts of the sessions. If you have any feedback about the summary, please contact lucy.fisher@thomsonreuters.com.
Discover more on this topic at Pharma Customer Engagement USA 2026 (October 27-28, Philadelphia) - where commercial, marketing, medical, data and AI pioneers converge. Explore the agenda here.
